

Summit Corporation plc
(‘Summit’ or ‘the Company’)

RESULT OF GENERAL MEETING

Oxford, UK, 19 July 2013 – Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and *C. difficile* infection, announces that at a General Meeting of the Company held earlier today, the resolutions, as set out in the Notice of General Meeting annexed to the circular to shareholders dated 3 July 2013, were duly passed, thereby enabling the proposed fundraising announced on 3 July 2012 to proceed.

The details of the proxy votes cast will be available shortly on Summit’s website (www.summitplc.com).

An application has been made to AIM, a market of the London Stock Exchange, for the admission of the 92,269,391 new Ordinary Shares. It is expected that Admission will become effective on or around 23 July 2013 and that dealings in the new Ordinary Shares will commence at 8.00 a.m. on or around 23 July 2013. Following Admission, the Company will have 446,357,841 Ordinary Shares in issue.

- END -

Notes to Editors

About Summit

Summit is an Oxford, UK based drug discovery and development Company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and *C. difficile* infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and follow Summit on Twitter ([@summitplc](https://twitter.com/summitplc)).

For more information, please contact:

Summit

Glyn Edwards / Richard Pye

Tel: +44 (0)1235 443 951

Nomura Code Securities

(Nominated Adviser and Joint broker)

Chris Collins / Jonathan Senior / Giles Balleny

Tel: +44 (0)20 7776 1200

Hybridan LLP

(Joint broker)

Claire Louise Noyce / William Lynne

Tel: +44 (0)207 947 4350 / 4361

Peckwater PR

(Financial public relations, UK)

Tarquin Edwards

Tel: +44 (0)7879 458 364

tarquin.edwards@peckwaterpr.co.uk

MacDougall Biomedical Communications

(US media contact)

Michelle Avery

Tel: +1 781-235-3060